Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilomilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B known ✓ | Q07343 | 20/20 | 0.98 |
| ▸ | PDE4A known ✓ | P27815 | 19/20 | 0.98 |
| ▸ | PDE4C known ✓ | Q08493 | 19/20 | 0.98 |
| ▸ | PDE4D known ✓ | Q08499 | 19/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilomilast SCHEMBL13777301 | 0.99 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL26372 | 0.99 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL27515 | 0.99 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL5975855 | 0.99 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL27516 | 0.99 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL29107422 | 0.98 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL7130621 | 0.98 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL7130626 | 0.98 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL7124080 | 0.96 | PDE4B (0.94) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL28381093 | 0.95 | PDE4B (0.92) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030083507-A1 | Treating chronic bronchial asthma by activating adenylate cyclase and inhibiting phosphodiesterase; principal airway smooth muscle relaxation; suppresses cell degranulation; from an oxaspiro-2.5-octane-2,6-dinitrile analog | SMITHKLINE BEECHAM CORPORATION | 2003-05-01 | — | — | US | claimed |
| US-20020082440-A1 | METHOD FOR PREPARING SUBSTITUTED 4-PHENYL-4-CYANOCYCLOHEXANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION | 2002-06-27 | — | — | US | claimed |
| CN-102772411-A | Combination of HMG-COA reductase inhibitors, such as roflumilast, roflumilast-N-oxide with a phosphodiesterase 4 inhibitor, rosuvastatin, for the treatment of inflammatory pulmonary diseases | NYCOMED GMBH | 2012-11-14 | — | — | CN | disclosed |
| CN-102764440-A | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | NYCOMED GMBH | 2012-11-07 | — | — | CN | disclosed |
| CN-101484166-B | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | NYCOMED GMBH | 2012-09-05 | — | — | CN | disclosed |
| CN-101484166-A | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | NYCOMED GMBH (DE) | 2009-07-15 | — | — | CN | disclosed |
| EP-1043930-A4 | METHOD FOR PREPARING SUBSTITUTED 4-PHENYL-4-CYANOCYCLOHEXANOIC ACIDS | SMITHKLINE BEECHAM CORP (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030083507-A1 | Treating chronic bronchial asthma by activating adenylate cyclase and inhibiting phosphodiesterase; principal airway smooth muscle relaxation; suppresses cell degranulation; from an oxaspiro-2.5-octane-2,6-dinitrile analog | SMITHKLINE BEECHAM CORPORATION | 2003-05-01 | — | — | US | disclosed |
| US-6452022-B1 | HEATING ALKALI OR ALKALINE EARTH METAL HALIDE, AND 6-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL))-1-OXASPIRO(2.5)OCTANE-2,6 -DICARBONITRILE IN SOLVENT; ADDING STRONG BASE, REMOVING WATER AND SOLVENT | SMITHKLINE BEECHAM CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20020082440-A1 | METHOD FOR PREPARING SUBSTITUTED 4-PHENYL-4-CYANOCYCLOHEXANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION | 2002-06-27 | — | — | US | disclosed |
| EP-1043930-A1 | METHOD FOR PREPARING SUBSTITUTED 4-PHENYL-4-CYANOCYCLOHEXANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999018793-A1 | METHOD FOR PREPARING SUBSTITUTED 4-PHENYL-4-CYANOCYCLOHEXANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083507-A1 | Treating chronic bronchial asthma by activating adenylate cyclase and inhibiting phosphodiesterase; principal airway smooth muscle relaxation; suppresses cell degranulation; from an oxaspiro-2.5-octane-2,6-dinitrile analog | PDE3A, PDE3B, PDE2A | PDE4B 13/4885PDE4A 10/4885PDE4C 23/4885 |
| US-20020082440-A1 | METHOD FOR PREPARING SUBSTITUTED 4-PHENYL-4-CYANOCYCLOHEXANOIC ACIDS | PCCA, CA6, CA4 | PDE4B 2865/4885PDE4A 2842/4885PDE4C 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.